Markets and sells insulin and other diabetes therapies in India, anchored on Lantus, Toujeo and the fixed-dose combination Soliqua. Alongside the diabetes franchise, the company distributes a legacy portfolio of cardiovascular, CNS and oral anti-diabetic brands through partnership agreements, with management describing this as the second pillar of a transformed business model. Public-sector expansion into CGHS, ESI, railways, defence and state rate contracts is a stated growth lever, alongside Tier 2/3 city penetration. Exports are a residual line — they collapsed after the 2020 divestment of the Ankleshwar manufacturing site to Zentiva, with Russia and South Africa now partially offsetting the gap; management says exports are only ~8% of PBT. No new product launches are planned for 2026; the development pipeline referenced is Teizeild, Brivekimig and Frexalimab. Costs are dominated by personnel and operating expenses, with FY26 opex down 17% on a partnership-driven restructuring tied to the Emcure deal. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Diabetes franchise, Partnership business, Exports. Insulin/diabetes-focused pharmaceutical pure-play with a partnership-distributed legacy portfolio.
| ₹ crore · consolidated | FY24 |
|---|---|
| Revenue | — |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | — |
| ROE % · ROCE % | — · — |
| Debt / equity (x) | — |
| Cash from operations | — |
| Capex | — |
| ₹ crore | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Revenue | 706 | 715 | 694 | 732 | 464 | 524 | 515 |
| Profit before tax | 183 | 210 | 189 | 188 | 92 | 113 | 122 |
| Net profit | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS (₹) | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Supreme Court dismisses Sanofi's plea to quash criminal proceedings in CBI case | regulatory legal | high | — | — |
| 31 Aug 2026 · Sanofi India gets GST show cause notice over product classification | regulatory legal | high | — | — |
| 13 Aug 2026 · Sanofi India gets GST refund of about Rs.1.33 crore sanctioned | regulatory legal | high | — | — |
| 11 Aug 2026 · Sanofi India wins Rs 72.71 lakh tax relief in TDS appeal for AY 2019-20 | regulatory legal | high | — | — |
| 10 Aug 2026 · Sanofi India Q2 FY26 transcript: diabetes up 17% in H1, PBT up 19% | investor communications | medium | — | — |
| 6 Aug 2026 · Investor/Analysts Call Video Recording Uploaded | investor communications | low | — | — |
| 5 Aug 2026 · Sanofi India publishes Q1 FY27 financial results in newspapers | compliance | minimal | — | — |
| 5 Aug 2026 · Sanofi India Q2/26: 8% domestic sales growth, PBT up 19% on diabetes strength | investor communications | medium | — | — |
| 4 Aug 2026 · Sanofi India Q2 FY26: Net sales up 6%, PBT jumps 19% | results | high | — | — |
| 4 Aug 2026 · Sanofi India Q2: PAT up 20%, diabetes portfolio grows 14%, board reconstituted | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 17.2 | 28.9 | 46 of 169 | 73% |
| P/B | 8.2 | 3.3 | 142 of 163 | 13% |
| ROCE | 48.3 | 10.8 | 5 of 183 | 98% |
| ROE | 48.0 | 10.4 | 6 of 171 | 97% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 25.7 | 17.5 | 49 of 165 | 71% |
| Revenue growth | (25.8) | 16.3 | 145 of 161 | 10% |
| Profit growth | (33.7) | 30.9 | 122 of 158 | 23% |
| Market cap | 7091 | 839 | 50 of 182 | 73% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
